Member Info for CJ39

I would buy back in here now except for the fact the FTSE is so ridiculously high. It’s only about 100 points of the all time ever high which I can’t get my head around given the cost of living crisis and high inflation rates.
Can it really go much higher? Only about 3 months ago the FTSE was at a 3 year low. I’m just watching for the time being but I do like Aviva.

Hi radar, I do hear what you say, it is frustrating that after such a great RNS on 10/10/2022 which took the share price up to about 8p then the share price has almost halved back down to around 4.5p now but I put that solely down to the fact that there has been little news since then and loads of people were selling out for a profit. I've seen this many times on AIM oil and mining shares after good news. AIM shares are really sensitive to numbers being bought and sold.
The Stalicla deal is in place, if all goes as hoped that is a jackpot money spinner in itself but from the sounds of it that is small fry compared to if the SFX drug proves effective for treating cancers.
Sure there is risk, poor results on clinical trials will hit the share price and that is the risk. But if things go to plan which initial results appear to be encouraging, this would be unbelievably exciting.
£12m market cap for a company that has potential to earn up to £133m on the Stalicla deal and has other clinical trials for other disorders and diseases which could strike huge deals. Time will tell, if it turns out a dud I'll be the first to say well done and thanks for warning us. If it goes how I hope it does I'll be posting saying you should have listened to us.
Are you invested in any shares you would recommend?

Come on radar, elaborate on why you think this will go down a lot further. I’ve always got time for those who are realistic and not rampers but you need to tell us why.

DSFLAT and PF-Builder, I share your thoughts totally. I really feel that Evgen have got something big on their hands here, it seems somewhat of a miracle drug that has excellent positive effects on so many disorders and diseases. The market cap is currently £13m which feels an insulting low amount given that there are cash reserves of over £7m and the Stalicla deal if all goes to plan could rake in £133m and that is just one deal. If the clinical trials are successful to treat the different cancers then there is potential for enormous deals to be struck. Fully funded for the next two years is re-assuring to know no dilution of shares. There are of course always risks, if clinical trials are not successful then that would be damaging to the share price. But I just think this is the share that has the potential to be massive and I would kick myself if I wasn't invested in it when it looks so promising.
Fingers crossed for a really good year here.

I think this is a really exciting share, the potential is huge here and with the company fully funded for the next two years there seems little risk of any dilution/placing of shares. It’s a free hit this. There could be up to $160m worth of payments coming from the Stalicla deal recently announced, plus there are lots of other trials taking place. The share price has only gone down because short termers have sold out again. I’ve managed to add to my holding, at these bargain basement levels. It’s going to take time but I really believe this will rise significantly in time.

Thanks Mazik, your post has helped me understand so much more about EVG. What a prospect this share is with plenty other irons in the fire. It’s a no brainer to hold this share. It’s going to take time but the potential is huge.

Thanks proinvestor, that’s a really great write up, thanks for explaining. I’ve certainly learnt a lot from your post. Definitely a share to hold and put in the drawer for the future.

I’m confused. Apologies Muzak, having read different articles it seems like you are right and in that case as you say why is the market cap just £16m if payments. I don’t think it’s overly clear though as the article mentions low to medium double digit royalties. Also why does the latest RNS say company is fully funded until end of 2024?

For me, EVG feels like a free hit. They are fully funded to the end of 2024, not sure if that refers to Dec 2024 or the end of their financial year 2024/5. So no fear of placings or share dilutions. The Sulphorophane drug that they have developed appears to have a lot of health benefits and works to treat many different illnesses and conditions. If the clinical trials are successful hopefully they will secure big deals to supply the drugs and the money will pour in. If they are successful it’s a multi bagger. If nothing happens in a years time I think you should be able to get out largely unscathed.

The £160m payment you mention is not for EVG, it’s for Stalicla. If I’m reading the RNS right the total expected payments from Stalicla will be $6m.

Very optimistic with this share. Fully funded for the next two years so no fears of any placing/dilution of shares. The share price is low here, can’t see any reason for it to drop apart from short term holders selling out. Lots of potential that this can increase. Therefore very happy to hold this share.

I’m quite happy for the drop, I bought in around the 5p mark and wished I had bought more. If this drops a little further I’ll happily add more. This share price is sensitive to buys/sells but I like that as it gives more opportunities to make profits. It’s not buys that will make this share price rise to the levels we hope for, it’s good news updates.

Definitely agree on all your points Devon. I wouldn’t invest in the shares I follow and trust at these sky high prices with all the problems on-going, as you say the winter has just started, the energy bills are starting to get real, the economy and markets are surely going to take a hit. Got to take advantage of these opportunities to maximise returns. It’s impossible to know when is the right price to sell out or buy in, it is so frustrating if you sell out and see the share price rise significantly but is it really going to happen in current market conditions?

I’ve been following this share since the rise about 6 weeks ago. It is one of the most exciting shares I have looked at for quite a while.
Having looked at RNS’ going back 3 years I feel like I’ve got some understanding of the company and the prospects of the company. When EVG released news in 2019 that results of one trial being unsuccessful it felt a huge blow at the time and the share price took a battering. But since then the Sulforaphane drug has had lots of positive test results and it does seem like EVG are on to something. The recent deal with the Swiss company felt like the start of a real upturn in fortunes. It would appear from the updates and annual results that EVG are funded for probably the next two years so at present no fear of any placings or dilution of shares.
EVG have a lot of projects they are working on and some appear to have real potential to be successful.
They do need to secure some more deals though to rake more money in to help protect the cash flow. As others have pointed out the stream of news isn’t too frequent which often makes the share price drop.
I think the half year report next week sounds like it should be positive. My thoughts are that there shouldn’t be too much risk of the share price dropping much over the next six months but there is potential of some good news which could see the share price increase. Not a cert that it’s going to take off but very promising. Definitely a share I’m happy to be invested in for the time being.

I’ve sold out today at 450p. This is my fav share and it’s as solid as houses… but we know this share has a tendency to swing. I am really pleased with how this share recovered from the 380p range not long ago. But it’s been a steady climb with good updates and the FTSE rising back from 7000 to 7500. My thoughts here is that the FTSE 100 index is really quite high, not far off a 3 year high which feels strange given the cost of living crisis. Can the FTSE increase much more? It’s quite a while before ex dividend date so I’m happy to sell for now and have money safe and look to buy back in at a cheaper price - hoping it doesn’t increase.
On other shares I am invested in, EVG is now the only share I’m invested in at present, not in for very much, just a few grand. This is in no way some ramping post on it, it’s far from a cert to increase, it feels a bit of a gamble but I feel like there is a lot more positive value than negative value in that one. Worth a look - any feedback would be welcome.

I’ve felt like this has been one of the easier shares to predict how the share price would go in recent months. I was confident this would reach £120 and to be honest after the two RNS’ earlier this month I fancied the share price to push on to £130. However since then it’s just bounced between £110 and £120. The recent RNS’ didn’t go down as well as I had hoped, there feels like there are doubts about market share in US sliding a little, the Australian and Irish business falling and there is always the gambling commission white paper uncertainty hanging over UK betting companies. I think at present the share price seems quite reasonable, I don’t see it moving much either way at present. So for that reason I am selling out for the time being.
On other shares I’m invested in, EVG is one I’m intrigued by. Half year results due next week. By no means a cert it’s going to take off but looks well worth a gamble as they are funded for what appears to be the next two years with quite a lot of potential good news.

I agree with straightntrue that the 22m trade was a sell. The AIM is very sensitive to buys and sells in terms of share price movement. If that was a buy the share price would have risen today.
On another note, I saw this share recommended in some online article not long ago, the share price went past 4p after the article was written. Very disappointing to see the share price halve from there so soon.

Radar, I would have said the same thing a year ago with no prospect of money rolling in short term but it feels like things are happening now. There is money coming in now and if these medicines that EVG are developing are approved and demanded this will be a very profitable share. There is risk of course but there is a feeling that things are starting to take off here.

https://www.sharesmagazine.co.uk/news/shares/retailer-joules-is-going-into-administration-what-happens-to-my-shares

I once lost a few grand in Afren when they went into administration, it’s a sickener.
It’s always risky investing in shares of a company who are in financial turmoil, the Joules brand was good, I liked their clothes, had they managed to re-invent themselves as an online business and cut out the crazy rents, rates, heating, employee costs I am sure that they would have come good. Their brand is well known. It really does signal the end for so many retail outlets, Councils need to help small companies not clobber them with high rates.
I remember Thomas Cook were once in a similar position and survived and the share price rocketed, so I can understand the temptation to invest here in recent times. Shame it failed, good luck with future investments.

Massachusetts Financial Services Group sold 263,879 shares in Flutter this week. I was scratching my head why this was struggling this week.
I am so confident in this share to rise short, medium and long term.